Decipher Prostate

Active Surveillance

2. Herlemann A, et al. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. *Prostate Cancer Prostatic Dis* 2019. [https://doi.org/10.1038/s41391-019-0167-9](https://doi.org/10.1038/s41391-019-0167-9)


Definitive Therapy


Early Radiation after Surgery


**Salvage Therapy after Surgery**


**GRID**


78. Salami SS, et al. Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 2018;3(21). [https://doi.org/10.1172/jci.insight.123468]


81. Torres A, et al. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63. *Prostate* 2018;78(12):896-904. [https://doi.org/10.1002/pros.23646](https://doi.org/10.1002/pros.23646)


100. Tse BWC, et al. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. *Oncogene* 2017;36(24):3417-27. [https://doi.org/10.1038/onc.2016.482](https://doi.org/10.1038/onc.2016.482)


124. Zhao SG, et al. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. *Prostate Cancer Prostatic Dis* 2015;18(3):229-36. [https://doi.org/10.1038/pcan.2015.22](https://doi.org/10.1038/pcan.2015.22)

125. Chakravarty D, et al. The oestrogen receptor alpha-regulated IncRNA NEAT1 is a critical modulator of prostate cancer. *Nat Commun* 2014;5:5383. [https://doi.org/10.1038/ncomms6383](https://doi.org/10.1038/ncomms6383)


Decipher Bladder


Reviews


159. Gadzinski AJ, Cooperberg MR. Prostate Cancer Markers. *Cancer Treat Res* 2018;175:55-86. [https://doi.org/10.1007/978-3-319-93339-9_3](https://doi.org/10.1007/978-3-319-93339-9_3)


